S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIBJuan Miguel Bergua Burgués, Pau Montesinos, Jordi Esteve et al.|HemaSphere|2023Cited by 6
Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemiaJoaquín Martínez‐López, Juan Ballesteros, Pau Montesinos et al.|Medicine International|2022Cited by 4
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA GroupsSusana Vives, Pau Montesinos, David Quintela et al.|Cancers|2024Cited by 4
A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema TrialJuan Miguel Bergua Burgués, Pau Montesinos, Raquel Tarazona et al.|Blood|2023Cited by 1